What do systematic reviews say?

Intervention not reported

• Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 274 participants
  Low

Intervention not reported

• Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 267 participants
  Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 509 participants
  Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with placebo, on combination therapy (moderate certainty).

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  OR 0.26 [0.07, 1.06]
  3 studies · 492 participants
  Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 387 participants
  High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 310 participants
  High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 303 participants
  High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo, on combination therapy (moderate certainty).

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  OR 1.2 [0.66, 2.17]
  2 studies · 227 participants
  Moderate

Continuous positive airway pressure (CPAP) vs no CPAP

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Very low
• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 57 participants
  Very low

Continuous positive airway pressure (CPAP) vs sham CPAP

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 61 participants
  GRADE not reported

Continuous positive airway pressure (CPAP) vs sham CPAP

The review found no eligible studies for this question.

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 152 participants
  Low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Very low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 122 participants
  Very low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

The review found no eligible studies for this question.

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

It is very uncertain whether continuous positive airway pressure (CPAP) changes minor adverse events compared with phosphodiesterase type 5 inhibitors (very low certainty).

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  RR 1.33 [0.34, 5.21]
  1 study · 40 participants
  Very low

Continuous positive airway pressure (CPAP) vs no CPAP

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Very low

Continuous positive airway pressure (CPAP) vs no CPAP

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 57 participants
  Very low

Continuous positive airway pressure (CPAP) vs no CPAP

The review found no eligible studies for this question.

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found